SS-31 (Elamipretide)

What it is

SS-31 (elamipretide) is the first FDA-approved mitochondrial-targeted peptide. That sentence alone moves it above almost everything else in the longevity cluster: on September 19, 2025 the FDA granted accelerated approval to FORZINITY (elamipretide injection), sponsored by Stealth BioTherapeutics, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥30 kg — an ultra-rare genetic cardiolipin disorder affecting roughly 150 people in the US — and the trial data behind that approval, plus four other large human trials in other indications, gives SS-31 ~475 patients of published human safety data across exposures up to 168 weeks at 40 mg/day SubQ with ZERO serious adverse events. That’s a cleaner record than nearly any other longevity peptide.

Underneath the FDA-approval headline is something more interesting: a fundamentally different mechanism than every other peptide in this wiki. SS-31 doesn’t signal anything. It doesn’t bind a receptor. It doesn’t activate a growth pathway. It doesn’t modulate the immune system. It’s structural support — a positively-charged 4-amino-acid peptide that binds the negatively-charged phospholipid cardiolipin in the inner mitochondrial membrane, stabilizes it, and breaks the ROS-damage vicious cycle that is arguably the root engine of aging itself. “Structural support, not signaling” is Stillson’s framing, and it changes the safety calculus completely (more on that below).

The cleanest mitochondrial-peptide taxonomy comes from Stillson:

• Mitochondrial-DERIVED peptides = naturally produced by your mitochondria. MOTS-c and Humanin are the main two. They are signaling molecules your mitochondria already make.
• Mitochondrial-TARGETED peptides = synthetic, specifically designed to act on mitochondria. SS-31 / elamipretide is the prototype.

These are different mechanism categories that both belong in a serious mitochondrial protocol, doing complementary jobs. MOTS-c signals “build more mitochondrial machinery and burn fat.” SS-31 stabilizes the machinery you already have so it stops leaking electrons and damaging itself. The two are a stack, not a substitution.

How it works

Start with the problem SS-31 solves. The electron transport chain (ETC) lives on the inner mitochondrial membrane and is what generates ~90% of your cell’s ATP. The ETC is also where the vast majority of your reactive oxygen species (ROS) are produced — every working ETC leaks some electrons, those electrons become ROS, and ROS damage everything around them, especially the inner mitochondrial membrane itself.

The inner mitochondrial membrane is stabilized by cardiolipin, a uniquely-shaped, negatively-charged phospholipid. Cardiolipin holds the ETC complexes in place and is required for the membrane geometry the ETC needs to work efficiently. ROS damage cardiolipin. Damaged cardiolipin destabilizes the ETC. Destabilized ETC leaks MORE electrons. More electrons → more ROS → more cardiolipin damage → more ETC dysfunction → vicious cycle, snowball effect, accelerating mitochondrial failure. This is the engine that arguably drives much of aging, neurodegeneration, heart failure, kidney decline, and metabolic disease.

SS-31 breaks the cycle. It’s a tetrapeptide with a net positive charge — it’s electrostatically drawn to negatively-charged cardiolipin, accumulates in the inner mitochondrial membrane, binds cardiolipin, and stabilizes it. Stable cardiolipin → stable ETC → less electron leak → less ROS → less cardiolipin damage → more ATP. The vicious cycle becomes a virtuous one. SS-31 doesn’t activate the ETC, doesn’t push more electrons through, doesn’t signal anything to anyone — it’s structural support. That’s it. That’s the whole mechanism.

Why “structural-support-not-signaling” matters for safety. This is Stillson’s key insight, and it changes the safety calculus fundamentally:

• No cancer-promotion concern. No growth signaling, no receptor activation, no proliferation pathway. The theoretical-tumor-promotion concern that applies to BPC-157 (VEGF, FAK-paxillin) doesn’t apply here at all.
• No immune-dysregulation concern. No immune-pathway involvement. The PD-1-contraindication-class concern that applies to Thymosin Alpha-1 doesn’t apply here.
• No mitochondrial-overstimulation concern. SS-31 just stabilizes; it doesn’t activate. You can’t overdrive what you’re only holding in shape.
• No tachyphylaxis or tolerance. No receptors involved means no receptors to downregulate or desensitize. Continuous use doesn’t lose effect over time.

This is fundamentally a different safety profile than every other peptide in this wiki. Lift this framing for any SS-31 content.

What the research shows

Human evidence — extensive and unusually clean.

• Barth syndrome 10-patient extension trial — patients dosed at 40 mg SubQ daily for 168 weeks (over 3 years). Outcomes: 30–40% improvement in muscle strength and functional markers, ~50% improvement in heart function markers. Only adverse events: local injection-site reactions. This is the trial set that anchors the FDA approval.
• 218-patient mitochondrial-disorder safety trial — 40 mg SubQ daily × 24 weeks. Only AEs: injection-site reactions.
• 176-patient macular degeneration trial — 40 mg SubQ daily × 48 weeks. Only AEs: injection-site reactions. Outcome: didn’t show large effects on the macular endpoints — a negative-efficacy finding for that indication, but adds to the safety record.
• 71-patient heart failure trial — 4–40 mg SubQ daily × 28 days. Only AEs: injection-site reactions. Outcome: didn’t show meaningful effect on heart-failure endpoints in that population.
• Phase 2 CKD trial — SS-31 + renal-artery stenting — significantly improved kidney function vs. stenting alone in renal-artery-stenosis patients.

Total documented human exposure: ~475 patients across long-term trials. Zero serious adverse events. This is one of the strongest human safety profiles for any peptide in the KB.

Animal / preclinical — first-class evidence. Stillson’s clinical-priority ranking by evidence quality:

• Top tier — most excited (mechanistically and preclinically strongest, no human data yet):
  • Neurodegenerative disease (Alzheimer’s, dementia, cognitive decline) — multiple mouse studies showing improved learning + memory markers.
  • Traumatic Brain Injury (TBI) — mouse studies showing decreased post-injury brain damage + functional recovery.
• Close second:
  • Chronic Kidney Disease (CKD) — multiple mouse models (diabetic, age-related, obesity-driven) plus the Phase 2 stenting human trial above.
• Moderate — works but cheaper alternatives exist:
  • Diabetes / insulin resistance — mouse studies show effect; for most patients, MOTS-c / GLP-1s / standard insulin sensitizers are more cost-effective.
• Speculative but mechanism-plausible (anecdotal + mechanism only, no trials):
  • Chronic fatigue / Long COVID / post-viral syndromes — anecdotal patient reports + human ATP-improvement data; the mechanism (broken mitochondria → fatigue) is strong but no direct intervention trials exist.
• Less excited (negative or null human data):
  • Heart failure (71-patient trial null).
  • Macular degeneration (176-patient trial null).
• Other plausible: eye diseases, certain genetic mitochondrial disorders, fibromyalgia.

The age-stratification finding — critical for anti-aging use. Stillson: young mice (human-equivalent 20–30 years) given SS-31 showed NO positive effects. Mitochondrial dysfunction begins meaningfully at mouse-age 18 months ≈ human ~50 years. This is a peptide where the indication is “declining mitochondria,” and if your mitochondria are still working well, there is nothing for SS-31 to stabilize that wasn’t already stable. Don’t take SS-31 “just in case” in your 20s or 30s. The clinical recommendation is age 50+ OR lab-confirmed mitochondrial dysfunction at younger ages.

Where the evidence is thin. No long-term human longevity-cohort data (Russian-school or otherwise). The Phase 3 trials that exist are in specific disease populations (Barth, macular degeneration, heart failure, CKD), not in healthy aging adults — so the “does it extend healthspan in normal aging?” question rests on the animal data + the mechanism + the safety record + the early human Long COVID / chronic-fatigue anecdotal reports. That’s promising. It’s not proven the way the Barth indication is.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only outside their FDA-approved indication. This is not medical advice. Consult a qualified physician before beginning any protocol.

The protocol Stillson actually runs and recommends.

• Dose (Stillson’s clinical recommendation): Start at 5–10 mg/day SubQ. Increase in 5 mg increments. Max 40 mg/day (the dose used in all the long-term human trials).
• Route: Subcutaneous only. IV has been used in trials but SubQ is the standard. Do not use oral SS-31 — there is no human and no animal data on oral SS-31, and 4-amino-acid peptides don’t fit the di-/tri-peptide intestinal transporters, so oral absorption is expected to be poor. Stillson is direct: do not trust unsubstantiated oral SS-31 formulations.
• Frequency: Daily. SS-31 clears plasma in ~24 hours but accumulates in mitochondria — some studies used 2×/week successfully, but Stillson prefers daily 5–10 mg over 2×/week 17.5 mg for continuous support.
• Cycles: Stillson’s recommendation: 1 month on / 1 month off baseline. Human trials used SS-31 continuously for up to 168 weeks without tachyphylaxis or tolerance loss — there’s no biological reason to cycle. The 1-on/1-off recommendation is for skin recovery from daily injection sites + cost management, not biology.

Cost framing (this is the Alyve commercial unlock).

• Compounded SS-31 is approximately $1 per mg at higher quantities.
• 40 mg/day = $40/day ≈ $1,200/month — not sustainable for most people.
• 5–10 mg/day = $5–10/day = $150–300/month — the customer-accessible entry point and the actual Stillson clinical recommendation.

The clinical-trial dose was set for the most severe mitochondrial-dysfunction population on Earth (Barth syndrome). For anti-aging or post-viral or early-CKD use, 5–10 mg/day is the protocol — and at that dose, SS-31 becomes accessible at sustainable monthly cost.

Reconstitution math. SS-31 typically ships as a lyophilized powder, commonly 20 mg or 50 mg vials. For a 20 mg vial reconstituted with 2 mL bacteriostatic water, you get 10 mg/mL — and 5 mg = 0.5 mL = 50 units on a U-100 insulin syringe; 10 mg = 1 mL = 100 units (full syringe). For a 50 mg vial reconstituted with 2.5 mL bac water, you get 20 mg/mL — and 10 mg = 0.5 mL = 50 units. Inject water down the side, swirl gently, never shake. Reconstituted SS-31 stores in the fridge.

Source preference. Stillson explicitly prefers compounding pharmacy > research-use-only sites — directly aligned with the Alyve verified-vendor framing.

Stacking — the mitochondrial-defense cluster.

• MOTS-c — the mitochondrial-DERIVED partner. MOTS-c signals “build more mitochondrial machinery, burn fat, restore insulin sensitivity”; SS-31 stabilizes the machinery you already have. Mitochondrial-signaling + mitochondrial-structural.
• NAD+ — supports the glutathione cycle and the redox systems that neutralize ROS. SS-31 prevents ROS production at the ETC; glutathione + NAD-supported antioxidant defense neutralizes the ROS that still gets made. Synergistic.
• Glutathione (when added to the longevity branch) — the same redox-defense pair as NAD+.
• Epithalon — the genomic / telomere layer. Mitochondrial + genomic = the two clocks of cellular aging.
• Thymosin Alpha-1 — the immune-surveillance layer.
• The full mitochondrial-defense + restoration stack: SS-31 + MOTS-c + NAD+ + glutathione (and Epithalon + Thymosin Alpha-1 for the wider longevity-restoration cluster, BPC-157 for repair).

Age-stratified protocol guidance.

• Under 50, no clinical indication, no lab evidence of mitochondrial dysfunction: SS-31 is probably not for you yet. The mouse data is clear — young animals showed no benefit. Better use of money in the longevity cluster: build the foundation (BPC-157, MOTS-c, NAD+, Epithalon on cycle) before adding SS-31.
• 50+ OR lab-confirmed mitochondrial dysfunction at any age: 5–10 mg/day SubQ, 1 month on / 1 month off, alongside the mitochondrial-defense stack.
• Diagnosed mitochondrial-genetic disease (Barth syndrome, certain LHON variants): This is the FDA-approved indication; clinical management is appropriate.
• Post-TBI, post-COVID, post-viral chronic fatigue: Mechanism strong, evidence anecdotal — defensible to try at 5–10 mg/day for a 2–3-month trial with patient-reported outcomes as the monitoring metric.

Side effects & management

SS-31 has arguably the cleanest safety record in the entire peptide longevity cluster. Across 475+ documented patients exposed up to 168 weeks at 40 mg/day SubQ in long-term published trials, zero serious adverse events. The only consistent finding: injection-site reactions (mild redness, occasional irritation).

Why the safety profile is structurally different. Per the “structural support, not signaling” mechanism:

• No cancer-promotion concern — no growth signaling.
• No immune dysregulation — no immune pathway.
• No mitochondrial overstimulation — just stabilization, no activation.
• No tachyphylaxis or tolerance — no receptors to downregulate.
• No documented withdrawal syndrome.

Management:

• Rotate injection sites. This is the only consistently reported issue.
• The 1-month-on / 1-month-off cycle is largely to give the skin a break, not biology.
• If you are pregnant or trying to conceive: the data hasn’t been generated; defer.
• Genetic mitochondrial disease management: the Barth syndrome indication is the FDA-approved use case and is appropriately managed clinically.

Cost is the real limiter, not safety. At 40 mg/day the protocol runs ~$1,200/month, which is not where most people will land. At 5–10 mg/day it’s $150–300/month and accessible. The right dose is “the lowest dose that produces a meaningful effect,” which for most non-Barth users is in the 5–10 mg range.

Regulatory status

🎯 FDA accelerated approval, September 19, 2025 — FORZINITY (elamipretide injection), Stealth BioTherapeutics. ✅ Verified (FDA press announcement + Stealth press release). Approved indication: improve muscle strength in adult and pediatric Barth syndrome patients ≥30 kg. First FDA-approved mitochondrial-targeted peptide. Stealth is studying elamipretide in further indications (dry age-related macular degeneration, primary mitochondrial myopathy).

For off-label use, SS-31 sits in the research-chemical / compounded-peptide space the rest of this wiki covers. The FDA approval for Barth syndrome gives the molecule a regulatory anchor — it’s a real drug with a real label, not just a research chemical — which is a notable differentiator vs. every other compound in the longevity cluster.

The Alyve product

SS-31 is not in Alyve’s current launch catalog of 15 SKUs — top-tier roadmap candidate alongside Thymosin Alpha-1 and Kisspeptin (the three “FDA-track” peptides from the deep-research promotion set).

The case for prioritizing SS-31 on Alyve’s roadmap:

• 🎯 FDA-approved (Barth syndrome) — provides FDA-grade regulatory authority for the off-label catalog. Customers see “FDA-approved” and trust the broader catalog more.
• 475+ patients, zero serious AEs — exceptional safety story.
• Structural mechanism (no signaling) — fundamentally different safety calculus than every other peptide. Lifts directly into customer copy.
• Multi-disease application breadth — cognitive decline + TBI + early CKD + Long COVID + anti-aging + Barth.
• Cost-accessible at 5–10 mg/day — the Alyve compounded SubQ entry point makes the protocol sustainable at ~$150–300/month.
• No tachyphylaxis — continuous use is biologically fine; cycling is for skin/budget.

When SS-31 lands in the Alyve catalog, expect a 20 mg or 50 mg lyophilized vial with the same third-party Freedom Diagnostics COA (HPLC-UV purity + LC-MS identity confirmation) the rest of the line carries, at the same >99% purity standard Alyve has hit across all current 15 SKUs.

Why SS-31 needs a verified-COA vendor more, not less. SS-31 is a 4-amino-acid peptide with a positive net charge — easy to synthesize cheaply, but the counter-ion / salt form matters (TFA-salt contamination from synthesis is the recurring gray-market issue across the peptide world). Identity-confirmed, salt-form-disclosed, third-party-COA-tested SS-31 is the clean tier. Independent gray-market audits keep finding roughly 1 in 4 vials underdosed, mislabeled, or contaminated — that risk doesn’t go down just because the molecule is small. Alyve’s standard (US manufacturing + Freedom Diagnostics testing + >99% purity + lot-traceable) is the verified-clean tier the moment SS-31 lands.

Until SS-31 is in catalog, the practical pairing today is MOTS-c + NAD+ — the mitochondrial-derived signaling layer + the redox-support layer that SS-31 will sit on top of when it lands.

Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. Three vials of SS-31 at the 5–10 mg/day protocol = roughly 3–6 months of continuous protocol — the natural commit-size.

Sources

• best-in-class single-source SS-31 content: FDA approval announcement, mitochondrial-derived vs mitochondrial-targeted taxonomy, cardiolipin-stabilization vicious-cycle mechanism, “structural support not signaling” safety framing, 475-patient zero-AE safety record, age-stratified protocol (don’t use under 50 without lab-confirmed dysfunction), oral-bioavailability di-/tri-peptide-transporter explanation, 5–10 mg/day cost-accessible protocol, compounding-pharmacy > research-use-only-site source preference (= Alyve verified-vendor framing).
• SS-31 was graded B/yellow PRIMARY energy + SECONDARY heal-recover. The FDA approval and ZERO serious AEs across 475+ patients justify upgrading to A/green for the Barth indication + maintaining B/green for off-label. Meta.js update pending.
• confirmed SS-31 is NOT in current 15-SKU catalog.

Related: MOTS-c · NAD+ · Epithalon · Thymosin Alpha-1 · BPC-157 · Kisspeptin.